Despite the promise that many potential neuroprotective treatments for Parkinson disease (PD) have shown in preclinical studies, the benefits have not been replicated in recent clinical trials. In this Review, Athauda and Foltynie discuss the reasons for this 'failure to translate', and propose strategies to avoid such eventualities in the future, including improved trial design and repositioning of existing drugs. They also review the most promising drugs that are currently in preclinical development or clinical testing for their neuroprotective properties in PD.
- Dilan Athauda
- Thomas Foltynie
